Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Csl ADR CSLLY

Healthcare Biotechnology

CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures... see more

Add To Watchlist

Recent & Breaking News (OTCQX:CSLLY)

CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B

PR Newswire June 20, 2023

Injectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure

PR Newswire June 5, 2023

Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

GlobeNewswire May 18, 2023

Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

PR Newswire May 2, 2023

OTC Markets Group Welcomes CSL Limited to OTCQX

GlobeNewswire April 27, 2023

CSL Seqirus Proud to Attend and Present at 2023 Canadian Immunization Conference

Canada NewsWire April 25, 2023

CSL Behring Receives FDA Approval for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 50mL Prefilled Syringe

PR Newswire April 18, 2023

Tavneos® (avacopan) included in updated EULAR recommendations for the management of AAV

PR Newswire March 28, 2023

CSL Opens New, State-of-the-Art Vaccine Research and Development Facility in Waltham, Massachusetts

PR Newswire March 27, 2023

The Lancet Publishes Pivotal Phase 3 Data on CSL's First-in-Class Garadacimab for HAE

PR Newswire March 1, 2023

Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand

GlobeNewswire February 28, 2023

CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing

PR Newswire February 26, 2023

CSL's HOPE-B Data Published in the New England Journal of Medicine, Demonstrating Efficacy and Durability of HEMGENIX® (etranacogene dezaparvovec-drlb)

PR Newswire February 23, 2023

Biotech Leader CSL Again Named Among America's Best Employers by Forbes

PR Newswire February 21, 2023

CSL Announces Next CEO & Managing Director

PR Newswire December 12, 2022

CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics

PR Newswire December 12, 2022

CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment

PR Newswire December 10, 2022

U.S. Food and Drug Administration approves CSL's HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B

PR Newswire November 22, 2022

Next-Generation mRNA, Gene Therapy, Plasma Products, Monoclonal Antibodies, and Recent Acquisitions and Collaborations Highlight CSL R&D Day 2022

PR Newswire November 2, 2022

CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology

PR Newswire November 1, 2022